Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEHA Aesther Healthcare Acquisition	$9.96	$10.25	$8.20 ▼ $14.22	$131.78M	0.04	434,237 shs	1.29 million shs
CAPR Capricor Therapeutics	$10.00 -0.9%	$10.21	$3.52 ▼ $23.40	$456.77M	0.85	1.74 million shs	2.09 million shs
ETON Eton Pharmaceuticals	$18.90 -0.1%	$15.81	$3.18 ▼ $21.48	$506.86M	1.22	204,009 shs	428,570 shs
SBTX Silverback Therapeutics	$14.43 -6.8%	$13.78	$2.80 ▼ $8.97	$520.32M	0.6	337,931 shs	1.86 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEHA Aesther Healthcare Acquisition	0.00%	0.00%	0.00%	+0.01%	+0.01%
CAPR Capricor Therapeutics	0.00%	-2.44%	-15.68%	-26.85%	+76.06%
ETON Eton Pharmaceuticals	0.00%	-4.59%	+9.00%	+25.75%	+432.39%
SBTX Silverback Therapeutics	0.00%	-3.67%	+1.91%	+37.69%	+62.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AEHA Aesther Healthcare Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	1.7637 of 5 stars	3.5	1.0	0.0	0.0	2.5	0.8	0.6
ETON Eton Pharmaceuticals	3.2585 of 5 stars	3.5	5.0	0.0	0.0	3.9	0.8	0.6
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEHA Aesther Healthcare Acquisition	0.00	N/A	N/A	N/A
CAPR Capricor Therapeutics	3.00	Buy	$35.50	255.00% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	56.97% Upside
SBTX Silverback Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AEHA, ETON, SBTX, and CAPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00
5/20/2025	CAPR Capricor Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$31.00
5/16/2025	ETON Eton Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $26.00
5/14/2025	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00 ➝ $30.00
5/14/2025	ETON Eton Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$26.00 ➝ $28.00
3/20/2025	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00 ➝ $30.00
3/19/2025	ETON Eton Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $26.00
3/19/2025	ETON Eton Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $24.00
3/19/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
3/17/2025	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$77.00 ➝ $77.00
3/4/2025	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$77.00 ➝ $77.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEHA Aesther Healthcare Acquisition	N/A	N/A	N/A	N/A	($0.14) per share	N/A
CAPR Capricor Therapeutics	$17.36M	26.31	N/A	N/A	$0.73 per share	13.70
ETON Eton Pharmaceuticals	$48.33M	10.49	$0.00 per share	4,502.79	$0.60 per share	31.50
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	$7.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEHA Aesther Healthcare Acquisition	-$560K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	-$22.29M	-$1.42	N/A	N/A	N/A	-146.86%	-112.95%	-57.00%	8/6/2025 (Estimated)
ETON Eton Pharmaceuticals	-$940K	-$0.18	N/A	37.80	N/A	-15.81%	-36.29%	-16.84%	8/14/2025 (Estimated)
SBTX Silverback Therapeutics	-$89.48M	-$2.42	N/A	∞	N/A	N/A	-29.62%	-28.20%	N/A

Latest AEHA, ETON, SBTX, and CAPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CAPR Capricor Therapeutics	-$0.33	-$0.53	-$0.20	-$0.53	$3.16 million	$2.73 million
5/13/2025	Q1 2025	ETON Eton Pharmaceuticals	$0.09	$0.07	-$0.02	-$0.06	$14.33 million	$17.28 million
3/19/2025	Q4 2024	CAPR Capricor Therapeutics	-$0.31	-$0.16	+$0.15	-$0.16	$9.87 million	$11.13 million
3/18/2025	Q4 2024	ETON Eton Pharmaceuticals	-$0.02	-$0.02	N/A	-$0.02	$10.53 million	$11.65 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEHA Aesther Healthcare Acquisition	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEHA Aesther Healthcare Acquisition	N/A	0.29	0.29
CAPR Capricor Therapeutics	N/A	4.19	4.19
ETON Eton Pharmaceuticals	N/A	1.51	1.41
SBTX Silverback Therapeutics	N/A	67.87	67.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEHA Aesther Healthcare Acquisition	78.64%
CAPR Capricor Therapeutics	21.68%
ETON Eton Pharmaceuticals	27.86%
SBTX Silverback Therapeutics	74.89%

Insider Ownership

Company	Insider Ownership
AEHA Aesther Healthcare Acquisition	19.80%
CAPR Capricor Therapeutics	10.50%
ETON Eton Pharmaceuticals	16.03%
SBTX Silverback Therapeutics	34.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEHA Aesther Healthcare Acquisition	2,021	13.23 million	10.61 million	Not Optionable
CAPR Capricor Therapeutics	N/A	45.68 million	40.01 million	Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.17 million	Optionable
SBTX Silverback Therapeutics	83	36.06 million	23.65 million	Not Optionable

AEHA, ETON, SBTX, and CAPR Headlines

Recent News About These Companies

Silverback Therapeutics (NASDAQ:SBTX) Stock Price Down 3.8% - Here's Why

May 12, 2025 | marketbeat.com

Meet the Silverback, the Leader of the Troop

October 17, 2024 | pbs.org

10 Fun Facts About Mountain Gorillas

September 18, 2024 | nationalgeographic.com

CapstanTx secures $165 million to deliver precise in vivo cell engineering

July 28, 2024 | pharmaphorum.com

ARS Pharmaceuticals Inc (SPRY)

May 11, 2023 | uk.investing.com

Wild Isles

March 12, 2023 | wwf.org.uk

A look back at RNA Therapeutics – day one

February 24, 2023 | pharmaphorum.com

SPRY ARS Pharmaceuticals, Inc.

January 24, 2023 | seekingalpha.com

ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger

November 22, 2022 | 247wallst.com

Dr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeutics

November 18, 2022 | nasdaq.com

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

November 10, 2022 | finance.yahoo.com

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

November 8, 2022 | finance.yahoo.com

Silverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactions

October 28, 2022 | markets.businessinsider.com

FDA accepts ARS Pharma’s NDA for Neffy

October 24, 2022 | thepharmaletter.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERI

October 23, 2022 | kentuckytoday.com

Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis

October 21, 2022 | finance.yahoo.com

Is Silverback Therapeutics Inc (SBTX) Stock a Good Investment?

October 19, 2022 | aaii.com

SHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWN

October 12, 2022 | bakersfield.com

INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT

September 17, 2022 | markets.businessinsider.com

SBTX Silverback Therapeutics, Inc.

September 15, 2022 | seekingalpha.com

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT

September 6, 2022 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEHA, ETON, SBTX, and CAPR Company Descriptions

Aesther Healthcare Acquisition NASDAQ:AEHA

Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses primarily in the pharmaceutical and medical devices sectors. The company was incorporated in 2021 and is based in New York, New York.

Capricor Therapeutics NASDAQ:CAPR

$10.00 -0.09 (-0.89%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$10.01 +0.01 (+0.06%)

As of 08:28 AM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Eton Pharmaceuticals NASDAQ:ETON

$18.90 -0.02 (-0.11%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$19.02 +0.13 (+0.66%)

As of 08:08 AM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Silverback Therapeutics NASDAQ:SBTX

$14.43 -1.06 (-6.84%)

As of 05/30/2025

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time